X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2024-04-01 | LH | Schroeder Mark S | EVP, Pres Diagnostics, COO | S - Sale | $217.29 | -6,477 | 5,036 | -56% | -$1,407,387 | ||||||
2024-04-01 | LH | Summy Amy B. | EVP, CMO | S - Sale | $217.29 | -3,500 | 3,975 | -47% | -$760,515 | ||||||
| D | 2024-03-28 | LH | Van Der Vaart Sandra D | EVP, GC | S - Sale+OE | $216.74 | -3,553 | 7,637 | -32% | -$770,077 | |||||
| D | 2024-03-07 | LH | Schroeder Mark S | EVP, Pres Diagnostics, COO | S - Sale+OE | $218.45 | -5,048 | 5,036 | -50% | -$1,102,736 | |||||
2024-03-07 | LH | Summy Amy B. | EVP, CMO | S - Sale | $218.45 | -227 | 3,859 | -6% | -$49,588 | ||||||
| D | 2024-02-21 | LH | Eisenberg Glenn A | CFO, EVP | S - Sale+OE | $215.97 | -34,504 | 23,595 | -59% | -$7,451,866 | |||||
2024-02-21 | LH | Divincenzo Jonathan P. | EVP, Pres, Central Labs, Intl | S - Sale | $215.49 | -500 | 3,401 | -13% | -$107,745 | ||||||
2024-02-13 | LH | Van Der Vaart Sandra D | EVP, GC | S - Sale | $226.45 | -237 | 7,637 | -3% | -$53,669 | ||||||
2024-02-08 | LH | Van Der Vaart Sandra D | EVP, GC | S - Sale | $222.06 | -259 | 7,637 | -3% | -$57,514 | ||||||
| D | 2024-02-05 | LH | Van Der Vaart Sandra D | EVP, GC | S - Sale+OE | $220.57 | -193 | 7,637 | -2% | -$42,570 | |||||
2023-11-16 | LH | Wilkinson Peter J | SVP, Chief Accounting Officer | S - Sale | $210.71 | -1,384 | 2,087 | -40% | -$291,627 | ||||||
2023-08-08 | LH | Anderson Kerrii B | Dir | S - Sale | $211.57 | -5,000 | 15,563 | -24% | -$1,057,833 | ||||||
2023-06-29 | LH | Van Der Vaart Sandra D | EVP, GC | S - Sale | $240.00 | -212 | 7,605 | -3% | -$50,880 | ||||||
| D | 2023-05-19 | LH | Kirchgraber Paul R | CEO, Covance Drug Development | S - Sale+OE | $216.91 | -4,300 | 12,946 | -25% | -$932,707 | |||||
| D | 2023-05-18 | LH | Schroeder Mark S | EVP, Pres Diagnostics, COO | S - Sale+OE | $216.77 | -1,500 | 6,687 | -18% | -$325,155 | |||||
2023-03-31 | LH | Schroeder Mark S | EVP, Pres-Diagnostics Lab | S - Sale | $225.81 | -3,897 | 6,687 | -37% | -$879,982 | ||||||
| D | 2023-02-21 | LH | Kirchgraber Paul R | CEO, Covance Drug Development | S - Sale+OE | $250.58 | -8,000 | 9,069 | -47% | -$2,004,675 | |||||
2023-02-14 | LH | Schroeder Mark S | EVP, Pres-Diagnostics Lab | S - Sale | $247.63 | -309 | 6,687 | -4% | -$76,518 | ||||||
| D | 2023-02-07 | LH | Van Der Vaart Sandra D | EVP, GC | S - Sale+OE | $243.01 | -219 | 5,341 | -4% | -$53,219 | |||||
| D | 2023-02-07 | LH | Schroeder Mark S | EVP, Pres-Diagnostics Lab | S - Sale+OE | $243.01 | -409 | 6,687 | -6% | -$99,391 | |||||
| D | 2023-02-03 | LH | Van Der Vaart Sandra D | EVP, GC | S - Sale+OE | $253.90 | -173 | 5,341 | -3% | -$43,925 | |||||
| D | 2023-02-03 | LH | Schroeder Mark S | EVP, Pres-Diagnostics Lab | S - Sale+OE | $253.90 | -324 | 6,687 | -5% | -$82,264 | |||||
2022-11-08 | LH | Schroeder Mark S | EVP, Pres-Diagnostics Lab | S - Sale | $232.67 | -1,116 | 6,687 | -14% | -$259,660 | ||||||
2022-09-26 | LH | Eisenberg Glenn A | CFO, EVP | S - Sale | $210.62 | -25,000 | 27,158 | -48% | -$5,265,576 | ||||||
2022-09-07 | LH | Caveney Brian J | EVP, Pres of Diagnostics | P - Purchase | $231.20 | +44 | 14,282 | 0% | +$10,251 | ||||||
| D | 2022-08-03 | LH | Eisenberg Glenn A | CFO, EVP | S - Sale+OE | $253.94 | -32,100 | 52,158 | -38% | -$8,151,449 | |||||
| D | 2022-08-01 | LH | Wilkinson Peter J | SVP, Chief Accounting Officer | S - Sale+OE | $258.40 | -2,576 | 1,914 | -57% | -$665,635 | |||||
2022-06-07 | LH | Caveney Brian J | EVP, Pres of Diagnostics | P - Purchase | $242.19 | +42 | 14,172 | 0% | +$10,174 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |